Abstract
The use of natural compounds has recently been reconsidered in modern clinical practice. A further advancement of these compounds is represented by the possibility of using innovative drug delivery systems that can improve the biopharmaceutical features of the delivered compounds. This review examines the recent developments in the field of delivery of natural drugs belonging to several therapeutic classes. In particular, the examined therapeutic classes are: antitumoral drugs, i.e. paclitaxel, doxorubicin, tea catechins and hypericin; anti-infective drugs, i.e. Melaleuca alternifolia and Artemisia arborescens L.; and antinflammatory/antioxidant drugs, i.e. cannabinoids and glycyrrhizinates used for topical application. In this review we highlight the utility of a suitable drug delivery system to improve the biopharmaceutical aspects of these drugs. The examined carriers are: vesicular carriers (liposomes, Ethosomes®, ultradeformable liposomes), nano- and microparticles, innovative gels, microemulsions.
Keywords: Natural compounds, antitumoral drugs, anti-infective drugs, antiinflammatory drugs, drug delivery systems, vesicles, nanoparticles, microemulsions, cyclodextrins
Current Bioactive Compounds
Title: Innovative Drug Delivery Systems for the Administration of Natural Compounds
Volume: 3 Issue: 4
Author(s): Donatella Paolino, Donato Cosco, Felisa Cilurzo and Massimo Fresta
Affiliation:
Keywords: Natural compounds, antitumoral drugs, anti-infective drugs, antiinflammatory drugs, drug delivery systems, vesicles, nanoparticles, microemulsions, cyclodextrins
Abstract: The use of natural compounds has recently been reconsidered in modern clinical practice. A further advancement of these compounds is represented by the possibility of using innovative drug delivery systems that can improve the biopharmaceutical features of the delivered compounds. This review examines the recent developments in the field of delivery of natural drugs belonging to several therapeutic classes. In particular, the examined therapeutic classes are: antitumoral drugs, i.e. paclitaxel, doxorubicin, tea catechins and hypericin; anti-infective drugs, i.e. Melaleuca alternifolia and Artemisia arborescens L.; and antinflammatory/antioxidant drugs, i.e. cannabinoids and glycyrrhizinates used for topical application. In this review we highlight the utility of a suitable drug delivery system to improve the biopharmaceutical aspects of these drugs. The examined carriers are: vesicular carriers (liposomes, Ethosomes®, ultradeformable liposomes), nano- and microparticles, innovative gels, microemulsions.
Export Options
About this article
Cite this article as:
Paolino Donatella, Cosco Donato, Cilurzo Felisa and Fresta Massimo, Innovative Drug Delivery Systems for the Administration of Natural Compounds, Current Bioactive Compounds 2007; 3 (4) . https://dx.doi.org/10.2174/157340707783220301
DOI https://dx.doi.org/10.2174/157340707783220301 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Antiandrogens in Prostate Cancer Endocrine Therapy
Current Cancer Drug Targets Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Hematological Targets of Radiation Damage
Current Drug Targets Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Celecoxib Upregulates Multidrug Resistance Proteins in Colon Cancer: Lack of Synergy with Standard Chemotherapy
Current Cancer Drug Targets Ovarian Aging: Melatonin Regulation of the Cytometric and Endocrine Evolutive Pattern
Current Aging Science Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology